将药物敏感性与分化状态关联可识别急性髓系白血病的有效联合方案
研究利用原代患者标本的体外药物筛选,在335例急性髓系白血病(AML)样本中发现p38 MAPK抑制剂doramapimod(DORA)与BCL2抑制剂venetoclax(VEN)联合较各自单药表现出广泛且增强的疗效,同时不损伤原代基质细胞。单药敏感性与不同的肿瘤细胞分化状态相关,联合可减轻这种差异。
要点
- 在335例AML患者样本中,DORA联合VEN较各自单药表现出广泛增强的疗效。
- 单药DORA和VEN的敏感性与不同且不重叠的肿瘤细胞分化状态相关。
- 联合增强疗效的机制可能源于抑制p38 MAPK介导的BCL2磷酸化,从而增强对VEN的敏感性。
核心结论
- 利用白血病分化状态对应的互补药物敏感性特征,如同时靶向p38 MAPK和BCL2,有机会在临床异质性大的AML中获得广泛且增强的疗效。
研究设计与样本
- 研究采用原代患者标本的体外药物筛选,纳入335例急性髓系白血病(AML)患者样本。
主要发现
- 在335例AML患者样本中,DORA联合VEN较各自单药表现出广泛且增强的疗效,同时不损伤原代基质细胞。
- 单药DORA和VEN的敏感性与不同且不重叠的肿瘤细胞分化状态相关。
- 单核细胞增多、M4/M5法国-美国-英国(FAB)分类及CD14+免疫表型与对DORA敏感和对VEN耐药相关,联合后可减轻这种差异。
- MAPK14和BCL2(分别为DORA和VEN的主要靶点)表达升高分别见于单核细胞白血病和未分化白血病。
- 在具有单核细胞样和祖细胞样转录组特征的AML中分别观察到DORA和VEN敏感性富集,联合后这些关联减弱。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Using ex vivo drug screening of primary patient specimens, we identified the combination of the p38 MAPK inhibitor doramapimod (DORA) with the BCL2 inhibitor venetoclax (VEN) as demonstrating broad, enhanced efficacy compared with each single agent across 335 acute myeloid leukemia (AML) patient samples while sparing primary stromal cells. Single-agent DORA and VEN sensitivity was associated with distinct, nonoverlapping tumor cell differentiation states. In particular, increased monocytes, M4/M5 French-American-British classification, and CD14+ immunophenotype tracked with sensitivity to DORA and resistance to VEN but were mitigated with the combination. Increased expression of MAPK14 and BCL2, the respective primary targets of DORA and VEN, were observed in monocytic and undifferentiated leukemias, respectively. Enrichment for DORA and VEN sensitivities was observed in AML with monocyte-like and progenitor-like transcriptomic signatures, respectively, and these associations diminished with the combination. The mechanism underlying the combination's enhanced efficacy may result from inhibition of p38 MAPK-mediated phosphorylation of BCL2, which in turn enhances sensitivity to VEN. These findings suggest exploiting complementary drug sensitivity profiles with respect to leukemic differentiation state, such as dual targeting of p38 MAPK and BCL2, offers opportunity for broad, enhanced efficacy across the clinically challenging heterogeneous landscape of AML.
引用
- Kurtz SE, Eide CA, Kaempf A, et al. Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia. Blood Adv. 2022. PMID: 35078224. doi:10.1182/bloodadvances.2021006307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。